Literature DB >> 7542644

The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.

O J Cordero1, C Sarandeses, J L López-Rodríguez, M Nogueira.   

Abstract

The aim of this study was to characterize the LAK cell subpopulation on which Prothymosin-alpha (ProT alpha) exerts its enhancing effect on cytotoxicity. We investigated the role of ProT alpha on LAK induction from peripheral blood lymphocytes (PBL) and NK-enriched cells, both cultured for 5 weeks with IL-2 and ProT alpha. The different cultures were separated into several subsets throughout the culture time using two color fluorescence activated cell sorting (FACS) and CD56, CD16, CD2 and CD8 monoclonal antibodies. Each cell subset was then tested for cytotoxicity against K562 and Daudi cells. The CD16+ CD2- subset from both, PBL and NK-enriched cells, was the only subset on which ProT alpha had an effect, significantly enhancing this subpopulation. Within the CD16 population, the cells CD16+ CD2+ were the most cytotoxic, although CD16+ CD2- cells were also cytotoxic. ProT alpha only potentiated the cytotoxicity of CD16+ CD2- subset significantly, with 29% and 41% for K562 and Daudi cells, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542644     DOI: 10.1016/0162-3109(95)00057-z

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  4 in total

1.  Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status.

Authors:  Preben Boysen; Ingrid Olsen; Ingvild Berg; Siri Kulberg; Grethe M Johansen; Anne K Storset
Journal:  BMC Immunol       Date:  2006-04-27       Impact factor: 3.615

2.  Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.

Authors:  Kyriaki Ioannou; Evelyna Derhovanessian; Eleni Tsakiri; Pinelopi Samara; Hubert Kalbacher; Wolfgang Voelter; Ioannis P Trougakos; Graham Pawelec; Ourania E Tsitsilonis
Journal:  BMC Immunol       Date:  2013-09-22       Impact factor: 3.615

Review 3.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

4.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.